Egle Therapeutics’ €40 Million Series A Funding Round

McDermott Will & Emery advised Egle Therapeutics on the deal. Gide advised the pool of investors, while Morgan, Lewis & Bockius advised Takeda Ventures.

Egle Therapeutics, which is a spin off of Institut Curie, an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, closed its €40 million Series A financing round. 

The round has been co-led by a pool of investors including LSP and BPI. Fund+, BioQube and Takeda Ventures, Inc. also participated in the round.

The new capital will be used primarily to advance the 2 lead assets into clinics, and further strengthen the internal drug pipeline.

The McDermott team who advised Egle Therapeutics and its managers comprised Emmanuelle Trombe (Picture) and Anne-France Moreau, partners, and Ludivine Rabreau, associate.

The Gide team included Pierre Karpik and Donald Davy.

Morgan, Lewis & Bockius UK advised Takeda Ventures with Olivier Chambord. 

Involved fees earner: Donald Davy – Gide Loyrette Nouel; Pierre Karpik – Gide Loyrette Nouel; Anne-France Moreau – McDermott Will & Emery; Ludivine Rabreau – McDermott Will & Emery; Emmanuelle Trombe – McDermott Will & Emery; Olivier Chambord – Morgan Lewis & Bockius;

Law Firms: Gide Loyrette Nouel; McDermott Will & Emery; Morgan Lewis & Bockius;

Clients: Bpifrance; Egle Therapeutics; LSP; Takeda Ventures Inc.;

Naoual Sadouqi

Author: Naoual Sadouqi